Rex Bionics appoints CEO
Mr. Simon, who has a 25-year track record in industry with significant success in a number of sub-sectors of healthcare including medical technology and medical devices, will formally join the Board of Rex Bionics as CEO in early October 2014.
Following a career which included working at NM Rothschild, McKinsey, Rexam and Smith & Nephew, where he was latterly President of the Endoscopy Division, Mr. Simon was Chief Executive of Biocompatibles International until its sale to BTG.
At Biocompatibles, he led a team that developed three medical products businesses: the Cardiovascular Stent business sold to Abbott Laboratories, the Contact Lens business sold to Cooper Industries, and the drug-eluting bead business which was sold as part of the disposal of the whole company to BTG. ■